目的分离乳腺癌细胞MDA-MB-435s中的侧群细胞(sidepopulation cells,SP),并比较侧群细胞和非侧群细胞(non-side population cells,NSP)的基本生物学特点.方法经Hoechst33342染色后,利用流式细胞技术分选乳腺癌细胞MDA-MB-435s中SP和NSP ...目的分离乳腺癌细胞MDA-MB-435s中的侧群细胞(sidepopulation cells,SP),并比较侧群细胞和非侧群细胞(non-side population cells,NSP)的基本生物学特点.方法经Hoechst33342染色后,利用流式细胞技术分选乳腺癌细胞MDA-MB-435s中SP和NSP 2个细胞亚群,比较2群细胞的形态、增殖和周期等特点.结果分选得到的SP细胞约占5.2%,其增殖速度较NSP细胞快,且细胞形态较粗大.NSP细胞的G1期所占比例为73.63%,高于SP细胞的G1期所占比例为54.16%.结论 SP和NSP细胞的形态有差异,SP细胞的增殖速度快于NSP细胞,NSP细胞的周期阻滞在G1期,提示SP细胞可能在乳腺癌细胞的生长过程中具有重要的作用.展开更多
目的:研究趋化因子CXCL12对人乳腺癌高转移细胞系MDA-MB-435失巢凋亡的影响。方法:实验组培养基中加入终浓度为50ng/ml的CXCL12,对照组为无CXCL12的DMEM培养基。两组细胞悬浮培养,建立人乳腺癌高转移细胞系MDA-MB-435失巢凋亡抵抗细胞...目的:研究趋化因子CXCL12对人乳腺癌高转移细胞系MDA-MB-435失巢凋亡的影响。方法:实验组培养基中加入终浓度为50ng/ml的CXCL12,对照组为无CXCL12的DMEM培养基。两组细胞悬浮培养,建立人乳腺癌高转移细胞系MDA-MB-435失巢凋亡抵抗细胞模型。MTT检测CXCL12对于失巢凋亡抵抗MDA-MB-435细胞系生长的影响,流式细胞仪检测两组细胞的凋亡情况,Transwell实验检测细胞侵袭能力改变。结果:CXCL12对于失巢凋亡抵抗MDA-MB-435细胞系在形态学方面与对照组相比无特异性改变。CXCL12作用组失巢凋亡抵抗细胞增殖能力低于对照组,凋亡率增加,侵袭能力增加,穿过膜细胞数明显高于对照组(28±3.0 vs 15±2.4,P<0.05)。结论:在人乳腺癌高转移细胞系MDA-MB-435失巢凋亡过程中,CXCL12能在一定程度上抑制失巢凋亡抵抗细胞的生长,但却能增加存活肿瘤细胞的侵袭性。展开更多
Background Recent studies have shown the LyP-1 peptide can home to either tumor lymphatics or the tumor cells and be internalized by targeted cells. This study aimed to investigate the possibility of using Na1311 labe...Background Recent studies have shown the LyP-1 peptide can home to either tumor lymphatics or the tumor cells and be internalized by targeted cells. This study aimed to investigate the possibility of using Na1311 labeled LyP-1 peptide as an imaging agent or a therapeutic radiopharmaceutical in breast carcinoma and its metastasis. Methods The 10-mer cyclic peptide contained the LyP-1 sequence （YCGNKRTRGC） was synthesized by the solid phase method. Disulfide bonds between the cysteines maintain the cyclic structure. The LyP-1 peptide was labeled with Na1311 using the chloramine-T method. The [1311] LyP-1 peptide and a [1311] control peptide were injected via tail vein into nude mice bearing MDA-MB-435 tumor xenografts. Biodistribution and imaging results in vivo were obtained. Results The labeling efficiencies of LyP-1 peptide reached 80%＋5% （n=5）. The radiochemical purity was about 96%. The radiochemical purity of the labeled compound remains 92% at 24 hours in human serum at 37~C. In the biodistribution studies, the [1311] LyP-1 peptide accumulated in the tumor to a higher level than in other organs. The [1311] LyP-1 peptide can successfully image the tumor in nude mice bearing MDA-MB-435 tumor xenografts. Conclusions The LyP-1 peptide could be effectively labeled with Na1311 and the labeled compound is stable in human serum at 37℃ for 24 hours. The high specificity of [1311] LyP-1 peptide suggests it may be a promising new radiotracer for identifying tumors.展开更多
文摘目的:研究趋化因子CXCL12对人乳腺癌高转移细胞系MDA-MB-435失巢凋亡的影响。方法:实验组培养基中加入终浓度为50ng/ml的CXCL12,对照组为无CXCL12的DMEM培养基。两组细胞悬浮培养,建立人乳腺癌高转移细胞系MDA-MB-435失巢凋亡抵抗细胞模型。MTT检测CXCL12对于失巢凋亡抵抗MDA-MB-435细胞系生长的影响,流式细胞仪检测两组细胞的凋亡情况,Transwell实验检测细胞侵袭能力改变。结果:CXCL12对于失巢凋亡抵抗MDA-MB-435细胞系在形态学方面与对照组相比无特异性改变。CXCL12作用组失巢凋亡抵抗细胞增殖能力低于对照组,凋亡率增加,侵袭能力增加,穿过膜细胞数明显高于对照组(28±3.0 vs 15±2.4,P<0.05)。结论:在人乳腺癌高转移细胞系MDA-MB-435失巢凋亡过程中,CXCL12能在一定程度上抑制失巢凋亡抵抗细胞的生长,但却能增加存活肿瘤细胞的侵袭性。
文摘Background Recent studies have shown the LyP-1 peptide can home to either tumor lymphatics or the tumor cells and be internalized by targeted cells. This study aimed to investigate the possibility of using Na1311 labeled LyP-1 peptide as an imaging agent or a therapeutic radiopharmaceutical in breast carcinoma and its metastasis. Methods The 10-mer cyclic peptide contained the LyP-1 sequence （YCGNKRTRGC） was synthesized by the solid phase method. Disulfide bonds between the cysteines maintain the cyclic structure. The LyP-1 peptide was labeled with Na1311 using the chloramine-T method. The [1311] LyP-1 peptide and a [1311] control peptide were injected via tail vein into nude mice bearing MDA-MB-435 tumor xenografts. Biodistribution and imaging results in vivo were obtained. Results The labeling efficiencies of LyP-1 peptide reached 80%＋5% （n=5）. The radiochemical purity was about 96%. The radiochemical purity of the labeled compound remains 92% at 24 hours in human serum at 37~C. In the biodistribution studies, the [1311] LyP-1 peptide accumulated in the tumor to a higher level than in other organs. The [1311] LyP-1 peptide can successfully image the tumor in nude mice bearing MDA-MB-435 tumor xenografts. Conclusions The LyP-1 peptide could be effectively labeled with Na1311 and the labeled compound is stable in human serum at 37℃ for 24 hours. The high specificity of [1311] LyP-1 peptide suggests it may be a promising new radiotracer for identifying tumors.
